Following a pivotal regulatory endorsement, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) stock experienced a notable increase on the US charts, which led ZVRA shares to rose 15.87%, closing at $7.30.
What FDA Committee has Endorsed?
Zevra (ZVRA) stated that the Genetic Metabolic Diseases Advisory Committee (GeMDAC) of the U.S. Food and Drug Administration (FDA) voted 11 in favor and 5 against their application. The ruling confirmed that arimoclomol is effective in treating individuals with type C Niemann-Pick disease (NPC) based on the data that was given.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Comprehensive clinical data, including pivotal trial results, long-term data from the arimoclomol open-label extension research, and information from expanded access initiatives, formed the basis of the positive recommendation. Zevra remains confident in arimoclomol’s clinical benefits for NPC and is optimistic about its progress toward approval.
FDA Review and Strategic Developments
The advantages and hazards of arimoclomol were reviewed by the GeMDAC, a group of specialists in medical genetics, metabolic diseases, epidemiology, and related subjects. The committee took into account new information that was given at the 45th Annual Meeting of the Society for Inherited Metabolic Disorders (SIMD) as well as comments from advocacy organizations, people with NPC, and independent specialists.
While the GeMDAC’s recommendation will be a significant input, it is not binding. The FDA will conduct its own independent review of the arimoclomol New Drug Application (NDA), with a Prescription Drug User Fee Act (PDUFA) action date set for September 21, 2024.
In a strategic development, Zevra has appointed Orsini Specialty Pharmacy as the partner for OLPRUVA oral suspension. OLPRUVA is a prescription drug intended for the long-term management of urea cycle disorders (UCDs) in both adult and pediatric patients. It is used in combination with certain therapy and dietary modifications.
Zevra is committed to treating rare diseases using cutting-edge research and data-driven approaches. The company seeks to provide ground-breaking treatments for illnesses for whom there are few other choices. The company’s distinct approach to medication research and marketing is indicative of its dedication to provide the rare illness community with innovative therapeutics that have a significant effect.
